ARQ531: Clinical Trials

7 trials of ARQ531, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 recruiting, 1 active not recruiting. 7 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Recruiting 6, Active not recruiting 1
Phase 11Active not recruiting 1

Follow ARQ531: new trials by email Literature Review of ARQ531 trials Research Report on ARQ531

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2RecruitingFred Hutchinson Cancer Center202026-12-012026-10-29
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma
Phase 2RecruitingRoswell Park Cancer Institute322026-11-152026-10-02
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 2RecruitingJennifer Woyach252026-11-012026-10-15
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Phase 2RecruitingCity of Hope Medical Center352026-10-232026-10-29
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib - Mantle Cell Lymphoma
Phase 2RecruitingCity of Hope Medical Center272025-01-222026-03-13
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Nemtabrutinib - Hematologic Malignancies, Waldenstroms Macroglobulinaemia
Phase 2RecruitingMerck Sharp & Dohme LLC4902021-04-052026-11-17
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Nemtabrutinib - Lymphoma, B-Cell, Small Lymphocytic Lymphoma
Phase 1 / Phase 2Active not recruitingArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1902017-06-262026-06-12

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (4)  ·  Hematologic Neoplasms (2)  ·  Leukemia, B-Cell (2)  ·  Lymphoma (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Waldenstrom Macroglobulinemia (2)  ·  Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Hemorrhagic Disorders (1)  ·  Hemostatic Disorders (1)  ·  Immune System Diseases (1)

Sponsors

City of Hope Medical Center (2)  ·  ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Jennifer Woyach (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Roswell Park Cancer Institute (1)

Countries

United States (7)  ·  Argentina (1)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Ireland (1)  ·  Israel (1)  ·  Italy (1)  ·  Poland (1)

Top investigators

Alexey V Danilov (1)  ·  Geoffrey Shouse (1)  ·  Jennifer A Woyach, MD (1)  ·  Jennifer Huang, MD, PhD (1)  ·  Matthew J Cortese (1)

Results publications

PMID 34398557, PMID 37930156

NIH funding

P30CA033572 (2), 2023 (1)